About Osteal Therapeutics
Osteal Therapeutics is a private company based in Dallas, Texas. It has reported $127,548,743 raised in six offerings on Form D since April 2018. Its chief executive is David Thompson.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 17, 2025 | Nov 5, 2025 | $15,602,151of $26.7M target | 10 | $1.5M | EquityRule 506(b) | Form D ↗ |
| May 22, 2024 | Jun 6, 2024 | $49,999,926of $49.9M target | 16 | $3.1M | EquityRule 506(b) | Form D ↗ |
| Aug 29, 2023 | Sep 12, 2023 | $22,285,675of $23.0M target | 19 | $1.1M | EquityRule 506(b) | Form D ↗ |
| Dec 17, 2021 | Dec 30, 2021 | $30,248,730of $32.3M target | 59 | $512K | EquityRule 506(b) | Form D ↗ |
| Nov 6, 2020 | Nov 23, 2020amended Jan 12, 2021 | $2,000,000fully sold | 25 | $80,000 | DebtRule 506(b) | Form D/A ↗1 earlier filing |
| Mar 26, 2018 | Apr 6, 2018 | $7,412,261of $7.7M target | 45 | $164K | EquityRule 506(b) | Form D ↗ |
| Total, six offerings | $127,548,743 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Osteal Therapeutics's Form D filed Nov 5, 2025.
MS
Martin Sands
Director
JC
Judson Cooper
Director
BB
Brian de Beaubien
Executive officer and director
DT
David Thompson
Chief Executive Officer and director
BM
Biren Mehta
Director
DK
Douglas Kohrs
Director
DC
David Cash
Director
RL
Rushu Luo
Director
EO
Erik Oros
Director
SP
Sonal Patel
Director
Earlier filings also listed Noam Krantz (director, last listed Dec 2021), Jude Paganelli (executive officer and director, last listed Jan 2021) and Renee Ryan (director, last listed Apr 2018).